Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

Recruiting Phase 1 Interventional Study
Angina Patients With Non-obstructive Coronary Artery Disease Coronary Microvascular Disease Coronary Microvascular Dysfunction (CMD)
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 1
Study type
Interventional
Purpose
Health Services Research
Participants needed
150 (estimated)
Sponsor
University of Virginia · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * • Female sex. * Age ≥18 years. * Willing and able to provide written informed consent. * Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent. * No evidence of obstructive epic…
Contacts

Patricia Rodriguez-Lozano, MD

434-982-1058

PR3GG@uvahealth.org

CONTACT

Shuo Wang

4349821058

VJR7CE@uvahealth.org

CONTACT